Revolution Medicines Inc. – Investors and Politicians Who Own It
RVMD, 3 share classes and securities
Investors who own it
15 tracked investors, $8.6B in shares, each from their latest 13F.
| Investor | Value | Share of portfolio |
|---|---|---|
Farallon Capital ManagementQ2 2026 | $2.5B | 11.7% |
Julian i Felix BakerBaker Bros. Advisors, Q2 2026 | $2.1B | 10.7% |
Darwin Global ManagementQ2 2026 | $2B | 54.5% |
Mark LampertBVF Partners, Q2 2026 | $555.3M | 14.2% |
| $551.8M | 0.56% | |
Behzad AghazadehAvoro Capital Advisors, Q2 2026 | $430.2M | 3.86% |
Anand ParekhAlyeska Investment Group, Q2 2026 | $123.5M | 0.32% |
Joseph EdelmanPerceptive Advisors, Q2 2026 | $98.8M | 1.48% |
Stanley DruckenmillerDuquesne Family Office, Q2 2026 | $74.8M | 1.44% |
| $51.2M | 0.03% | |
Daniel SchneebergerADAR1 Capital Management, Q2 2026 | $16.4M | 0.75% |
Joseph EdelmanPerceptive Advisors, Q2 2026 | $2.3M | 0.04% |
Howard MarksBondOaktree Capital Management, Q2 2026 | $1.4M | 0.02% |
Farallon Capital ManagementQ2 2026 | $1.1M | 0.01% |
Barry RitholtzRitholtz Wealth Management, Q2 2026 | $758.7K | 0.01% |
Politicians who own it
Estimated from annual disclosures and trades; values are rough estimates.
No member of Congress is estimated to hold this stock.
Investors buying and selling
| Investor | Action | Shares now |
|---|---|---|
| Farallon Capital Management | Reduced −0.3% | 14,582,796 |
| Behzad Aghazadeh | New | 2,170,000 |
| Mark Lampert | Reduced −16% | 3,356,782 |
| Alphabet (corporate investments) | Reduced −19% | 3,345,102 |
| Anand Parekh | New | 239,097 |
| Daniel Schneeberger | Added +4.3% | 145,079 |
Politicians trading it
Latest Congress trades disclosed under the STOCK Act; amounts are ranges.
No disclosed Congress trades in this stock.